大家健康（中旬版）
大傢健康（中旬版）
대가건강（중순판）
GOOD HEALTH FOR ALL
2015年
5期
148-149
,共2页
非糜烂性胃食管反流%莫沙必利%兰索拉唑%疗效
非糜爛性胃食管反流%莫沙必利%蘭索拉唑%療效
비미란성위식관반류%막사필리%란색랍서%료효
Non -erosive gastroesophageal reflux disease (NEGRD)%mosapride%lansoprazole%curative effect
目的：探讨莫沙必利联合兰索拉唑治疗非糜烂性胃食管反流的临床疗效。方法：以随机数字表法将2012年10月－2014年10月我院收诊的140例非糜烂性胃食管反流患者分为观察组（80例）与对照组（60例），观察组患者以莫沙必利联合兰索拉唑治疗，对照组患者以雷尼替丁联合多潘立酮治疗，比较两组的临床疗效及治疗前后食管动力。结果：观察组患者治疗总有效率显著高于对照组（92．5％ vs78．3％）（P ＜0．05）；治疗后两组患者的 LES 静息压力、食管体部远端波幅以及有效收缩率均较治疗前增加，且观察组较对照组显著增加（P ＜0．05）。结论：莫沙必利联合兰索拉唑治疗非糜烂性胃食管反流可显著抑制胃酸分泌、增加食管动力，临床疗效切实。
目的：探討莫沙必利聯閤蘭索拉唑治療非糜爛性胃食管反流的臨床療效。方法：以隨機數字錶法將2012年10月－2014年10月我院收診的140例非糜爛性胃食管反流患者分為觀察組（80例）與對照組（60例），觀察組患者以莫沙必利聯閤蘭索拉唑治療，對照組患者以雷尼替丁聯閤多潘立酮治療，比較兩組的臨床療效及治療前後食管動力。結果：觀察組患者治療總有效率顯著高于對照組（92．5％ vs78．3％）（P ＜0．05）；治療後兩組患者的 LES 靜息壓力、食管體部遠耑波幅以及有效收縮率均較治療前增加，且觀察組較對照組顯著增加（P ＜0．05）。結論：莫沙必利聯閤蘭索拉唑治療非糜爛性胃食管反流可顯著抑製胃痠分泌、增加食管動力，臨床療效切實。
목적：탐토막사필리연합란색랍서치료비미란성위식관반류적림상료효。방법：이수궤수자표법장2012년10월－2014년10월아원수진적140례비미란성위식관반류환자분위관찰조（80례）여대조조（60례），관찰조환자이막사필리연합란색랍서치료，대조조환자이뢰니체정연합다반립동치료，비교량조적림상료효급치료전후식관동력。결과：관찰조환자치료총유효솔현저고우대조조（92．5％ vs78．3％）（P ＜0．05）；치료후량조환자적 LES 정식압력、식관체부원단파폭이급유효수축솔균교치료전증가，차관찰조교대조조현저증가（P ＜0．05）。결론：막사필리연합란색랍서치료비미란성위식관반류가현저억제위산분비、증가식관동력，림상료효절실。
To study the clinical curative effect of non -erosive gastroesophageal reflux disease (NEGRD)treated with mosapride and lanso-prazole.Methods:From October in 2012 to October in 2014,140 cases of patients in our hospital diagnosed as NEGRD were divided into observation group (80 cases)and control group (60 cases)with random number table method.The patients in observation group were treated with mosapride and lansoprazole,and the control group was treated with ranitidine and domperidone.The clinical curative effect and the esophageal power before and after treatment of the two groups were compared.Results:The total effective rate of the observation group was significantly higher than the control group (92.5% vs78.3%)(P <0.05);In the two groups,LES resting pressure in patients after treatment,the distal esophageal body wave amplitude and shrinkage rate all increased,and those of the observation group increased significantly than the control group (P <0.05).Conclusion:Mosapride and lansoprazole can significantly inhibit gastric acid secretion of pa-tients with NEGRD,and increase esophageal power.The clinical curative effect is real.
